Search

everythinglearnresearchcommunity

for

Search:↓

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

The document concludes that more research is needed to understand and treat Beard Alopecia Areata due to limited current knowledge and evidence.

High-dose corticosteroids and methotrexate had a modest effect on severe childhood alopecia, but side effects and relapse were concerns.

PRP did not significantly regrow hair in alopecia areata totalis patients.

Some people with severe, long-lasting baldness responded well to a specific combination treatment.

Topical diphencyprone helped regrow hair in mice and rats with a condition similar to human hair loss.

Trichoscopy helps better understand and manage alopecia areata, improving patient outcomes.

A new algorithm effectively classifies Alopecia Areata, aiding early detection and treatment.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Alopecia Areata greatly affects the quality of life and mental health of Canadian patients and their caregivers.

Treating alopecia areata is difficult due to limited approved treatments, but new therapies like JAK inhibitors show promise.

An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.

Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.

Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Patients with severe alopecia areata have higher levels of MIF, which decrease after successful treatment.

Mindfulness-based cognitive therapy may reduce social anxiety and improve wellbeing in people with alopecia areata.

Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.

DPCP immunotherapy is effective for alopecia areata, and understanding influencing factors can improve treatment and satisfaction.

Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.

Tofacitinib may help treat severe hair loss, but more research is needed.

Stem cell therapy may help treat tough hair loss cases.

Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.

Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.

People with alopecia areata have higher levels of a heart disease marker than those without hair loss.

Nitrogen mustard was not very effective for hair regrowth in alopecia areata and has potential skin cancer risk.

Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

The PRP-like cosmetic with biomimetic peptides is potentially effective and safe for treating alopecia areata.